Categories
Top stories

Regional Outlook: Antiviral Therapies Market by Key Vendors, Challenges and Opportunities 2027

Global Antiviral Therapy Market size is expected to grow with a CAGR of 5.8% from 2019 to 2026 According to a study conducted by Research Dive. The global antiviral therapy market size was accounted at $48.1 billion in 2018 and is anticipated to garner $ 75.6 billion by 2026.

Increasing incidences of viral infections, growing awareness among public about these infections, rise in healthcare spending, growing R&D investments, and growing incidences of severe and deadly disorders in people are the key antiviral therapy market drivers responsible to boost the growth of global market during estimated period. In addition, development of broad-spectrum antibiotics and surge in profitable opportunities in the developing economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the growth of the market. On the other hand, huge costs involved in the manufacturing of these therapy and rise in the demand for alternative medicines such as homeopathy and naturopathy are expected to restrain the development of the market.

The HIV segment in the antiviral therapy market was valued at $16.4 billion in the year 2018 and is expected to increase with a growth rate of 5.4% throughout the estimated period. This is because of the rising occurrence of HIV infection across the globe. The majority of HIV antiviral drug usage has been seen in the North America region. Also, the consumption of antiviral therapy in African region is expected to increase and fuel the development of the market.

The online pharmacy segment is expected to grow at an increased speed by generating a revenue of $23.2 billion by the end of 2026, at a significant growth rate of 6.1% during the forecast period. On the other hand, the hospital pharmacy segment is anticipated to dominate the market by generating a revenue of $35.5 billion by the end of 2026, at a substantial growth rate of 5.5% throughout the forecast period. This is mainly due growing trends in the online shopping sector in the developed and developing countries. At present, the market share is mainly controlled by a few top pharmaceuticals as well as biotechnology companies.

Regionally, the market has been studied across Asia-Pacific, North America, Europe, and LAMEA. Asia-Pacific antiviral therapy market is anticipated to grow at an increased pace with a healthy growth rate of 6.5% during the forecast period, garnering $12.8 billion by the end of 2026. This is mainly due to factors such as the growing cases of HIV infection, growing awareness about HIV infection, and increasing collaboration between public and private sectors in this region. Furthermore, the North America antiviral therapy market held a leading position in the global antiviral therapy market in 2018. This region is anticipated to hold its lead position in the market throughout the forecast period by generating a revenue of $29.5 billion by 2026. This is attributed to factors such as the rising occurrence of HIV and hepatitis C infections, well-established market players in the region, growing healthcare awareness, rising elderly population, and increasing healthcare spending in this region. On the contrary, factors such as patent expiration and generic erosion of antiviral therapy are hindering the growth of the market in this region.

The key market players profiled in the report are F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Abbott Laboratories, AbbVie Inc., AstraZeneca Plc., Bristol- Myers-Squibb, Johnson & Johnson, Schering-Plough Corporation, and Merck & Co., Inc. These market players are undertaking several activities to grab a major share of the market and hold a leading position in the antiviral therapies industry. Some of these activities include new product launches, mergers and acquisitions, antiviral therapy market developments in current technology. These are some of the growth strategies implemented by these market players.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
+1 (917) 444-1262 (US) Toll
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

Categories
All News

Antiviral Therapies MarketDistinguished Technology Development with Major Production Goals Analysis by 2026

Research Dive in its latest published report estimates that the global antiviral therapies market will generate $66,016.5 million and exhibit a CAGR of 3.1% from 2020 to 2027.

Market Dynamics

The rising prevalence of viral infections such as HIV, hepatitis, and influenza and the growing demand for antiviral drugs in HIV treatment are the major factors estimated to bolster the growth of the global antiviral therapies market over the forecast period. In addition, the growing focus of manufacturers to develop innovative and cost-effective drugs by incorporating nanotechnology into antiviral drugs is projected to create massive growth opportunities for the global industry by 2027. However, the time consuming process to develop antiviral drugs and high costs associated with antiviral therapies is expected to hamper the market growth in the upcoming years.

Access to Free Sample of Dermacosmetics Market Report (Including Full TOC, tables & Figure) Here! @ https://www.researchdive.com/download-sample/78

Impact of COVID-19 Pandemic on the Industry

The COVID-19 pandemic has impacted the global antiviral therapies market in a favorable way in 2020. The growth of the industry during the unprecedented times is majorly due to growing cases of COVID-19 and increasing R&D activities to develop antiviral drug for coronavirus treatment. Besides, a various government bodies and manufacturers are taking initiatives such as collaborations to develop Covid-19 vaccine, which is expected to provide lucrative opportunities for the global industry in the upcoming years. For instance, in March 2020, Pfizer Inc. and BioNTech SE entered into a strategic collaboration to co-develop and distribute a potential mRNA-based coronavirus vaccine that prevents COVID-19 infection.

Key Segment Findings of the Market:

The research report categorizes the global antiviral therapies market into type, distribution channel, and region.

  • Based on type, the HIV antiviral drug sub-segment valued for largest share of antiviral therapies market in 2019 with 60.9% and is predicted to continue its dominance during the forecast period. This is majorly due to the rising occurrence of HIV cases across the globe.
  • Based on distribution channel, the hospital pharmacy sub-segment valued for $27,790.8 million in 2019 and is projected to grow at significant CAGR during the forecast period. This rapid growth can be attributed to growing geriatric population and viral infections around the world.
  • Based on region, the North America market for antiviral therapies accounted for $15,636.2 million in 2019 and is estimated to witness noteworthy growth by 2027. Growing cases of viral infections and rapid growth in aging population are the major factors expected to drive the regional market growth in the near future.

Prominent Market Players

The key players of the global Antiviral therapies industry include

  1. Gilead Sciences, Inc.
  2. GlaxoSmithKline plc
  3. F. Hoffmann-La Roche Ltd
  4. Abbott
  5. Bristol-Myers Squibb Company
  6. AstraZeneca
  7. Aurobindo Pharma
  8. AbbVie Inc.
  9. Johnson & Johnson Services, Inc.
  10. Merck & Co., Inc.  

These players are focusing on technological advancements, strategic collaborations, and drug approval & launches to gain a competitive in the global market.

For instance, in December 2019, GlaxoSmithKline Plc, a research-based pharmaceutical company, submitted a new drug application to the U.S. FDA seeking approval for ‘fostemsavir,’ an experimental HIV treatment in adults. The company has developed fostemsavir for use in combination with other antiretroviral agents in adults who have been beforehand taken treatments for HIV.

Checkout How COVID-19 impacts the Dermacosmetics Market. Click Here to Speak our Expertise before buying Report & Get More Market Insights @ https://www.researchdive.com/connect-to-analyst/78

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://industrialresearchworld.blogspot.com/

Categories
All News

Sales of Antiviral Therapies to Increase from Top End-use Industries During the Forecast Period

As per a report published by Research Dive, the global antiviral therapies market is expected to generate $75.6 billion by 2026, exhibiting a CAGR of 5.8% from 2019 to 2026. The global market is segmented based on drug type, distribution channel, and region. The report offers complete insights on drivers, challenges, opportunities, restraints, and key players of the market.

As per the analysts, the increasing occurrence of viral infections and growing awareness among public regarding these infections are the major factors predicted to foster the growth of global antiviral therapies market over the forecast period. Moreover, increasing R&D investments and the rise in healthcare spending are likely to create huge growth opportunities for the global market in the near future.

However, the rising demand for alternative medicines and high costs involved in the production of antiviral drugs are expected to be the major barriers for the market growth.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/78

HIV Antiviral Drugs Segment to be Most Lucrative

By drug type, the HIV antiviral drugs segment is expected to witness a significant growth by growing at a CAGR of 5.4% from 2019 to 2026. This segment is predicted to be most lucrative during the forecast period, owing to the rising occurrence of HIV infections around the world and the increasing usage of antiviral drugs in African economies.

Online Pharmacy Segment to Grow at Increased Rate

By distribution channel, the online pharmacy segment is anticipated to grow at an increased speed by garnering a revenue of $23.2 billion by 2026. This is majorly due to the rising trend in the online shopping sector.

North America Region to Dominate the Industry

By region, the North America market for antiviral therapies is expected to hold a dominant position in the global market throughout the forecast period. The dominance of this region is majorly attributed to various factors such as rising elderly population, growing occurrence of HIV and hepatitis C infections, and the presence of key players of the market.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/78

Prominent Industry Players

The major players operating in the global antiviral therapies market include –

  1. F. Hoffmann-La Roche Ltd.
  2. Gilead Sciences
  3. AbbVie Inc.
  4. Abbott Laboratories
  5. GlaxoSmithKline
  6. Bristol-Myers-Squibb
  7. Johnson & Johnson
  8. AstraZeneca Plc.
  9. Merck & Co., Inc.
  10. Schering-Plough Corporation.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://industrialresearchworld.blogspot.com/

Categories
All News

Antiviral Therapies Market Analysis, Size, Market Shares, Industry Challenges and Opportunities to 2026

As per a report published by Research Dive, the global antiviral therapies market is expected to generate $75.6 billion by 2026, exhibiting a CAGR of 5.8% from 2019 to 2026. The global market is segmented based on drug type, distribution channel, and region. The report offers complete insights on drivers, challenges, opportunities, restraints, and key players of the market.

As per the analysts, the increasing occurrence of viral infections and growing awareness among public regarding these infections are the major factors predicted to foster the growth of global antiviral therapies market over the forecast period. Moreover, increasing R&D investments and the rise in healthcare spending are likely to create huge growth opportunities for the global market in the near future.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/78

However, the rising demand for alternative medicines and high costs involved in the production of antiviral drugs are expected to be the major barriers for the market growth.

HIV Antiviral Drugs Segment to be Most Lucrative

By drug type, the HIV antiviral drugs segment is expected to witness a significant growth by growing at a CAGR of 5.4% from 2019 to 2026. This segment is predicted to be most lucrative during the forecast period, owing to the rising occurrence of HIV infections around the world and the increasing usage of antiviral drugs in African economies.

Online Pharmacy Segment to Grow at Increased Rate

By distribution channel, the online pharmacy segment is anticipated to grow at an increased speed by garnering a revenue of $23.2 billion by 2026. This is majorly due to the rising trend in the online shopping sector.

North America Region to Dominate the Industry

By region, the North America market for antiviral therapies is expected to hold a dominant position in the global market throughout the forecast period. The dominance of this region is majorly attributed to various factors such as rising elderly population, growing occurrence of HIV and hepatitis C infections, and the presence of key players of the market.

Prominent Industry Players

The major players operating in the global antiviral therapies market include –

  1. F. Hoffmann-La Roche Ltd.
  2. Gilead Sciences
  3. AbbVie Inc.
  4. Abbott Laboratories
  5. GlaxoSmithKline
  6. Bristol-Myers-Squibb
  7. Johnson & Johnson
  8. AstraZeneca Plc.
  9. Merck & Co., Inc.
  10. Schering-Plough Corporation.

Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/78

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://industrialresearchworld.blogspot.com/

Categories
Top stories

Emerging Trends: Antiviral Therapies Market Revenue, Growth Rates, and Industry Challenges in 2027

Global Antiviral Therapy Market size is expected to grow with a CAGR of 5.8% from 2019 to 2026 According to a study conducted by Research Dive. The global antiviral therapy market size was accounted at $48.1 billion in 2018 and is anticipated to garner $ 75.6 billion by 2026.

Increasing incidences of viral infections, growing awareness among public about these infections, rise in healthcare spending, growing R&D investments, and growing incidences of severe and deadly disorders in people are the key antiviral therapy market drivers responsible to boost the growth of global market during estimated period. In addition, development of broad-spectrum antibiotics and surge in profitable opportunities in the developing economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the growth of the market. On the other hand, huge costs involved in the manufacturing of these therapy and rise in the demand for alternative medicines such as homeopathy and naturopathy are expected to restrain the development of the market.

The HIV segment in the antiviral therapy market was valued at $16.4 billion in the year 2018 and is expected to increase with a growth rate of 5.4% throughout the estimated period. This is because of the rising occurrence of HIV infection across the globe. The majority of HIV antiviral drug usage has been seen in the North America region. Also, the consumption of antiviral therapy in African region is expected to increase and fuel the development of the market.

The online pharmacy segment is expected to grow at an increased speed by generating a revenue of $23.2 billion by the end of 2026, at a significant growth rate of 6.1% during the forecast period. On the other hand, the hospital pharmacy segment is anticipated to dominate the market by generating a revenue of $35.5 billion by the end of 2026, at a substantial growth rate of 5.5% throughout the forecast period. This is mainly due growing trends in the online shopping sector in the developed and developing countries. At present, the market share is mainly controlled by a few top pharmaceuticals as well as biotechnology companies.

Regionally, the market has been studied across Asia-Pacific, North America, Europe, and LAMEA. Asia-Pacific antiviral therapy market is anticipated to grow at an increased pace with a healthy growth rate of 6.5% during the forecast period, garnering $12.8 billion by the end of 2026. This is mainly due to factors such as the growing cases of HIV infection, growing awareness about HIV infection, and increasing collaboration between public and private sectors in this region. Furthermore, the North America antiviral therapy market held a leading position in the global antiviral therapy market in 2018. This region is anticipated to hold its lead position in the market throughout the forecast period by generating a revenue of $29.5 billion by 2026. This is attributed to factors such as the rising occurrence of HIV and hepatitis C infections, well-established market players in the region, growing healthcare awareness, rising elderly population, and increasing healthcare spending in this region. On the contrary, factors such as patent expiration and generic erosion of antiviral therapy are hindering the growth of the market in this region.

The key market players profiled in the report are F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Abbott Laboratories, AbbVie Inc., AstraZeneca Plc., Bristol- Myers-Squibb, Johnson & Johnson, Schering-Plough Corporation, and Merck & Co., Inc. These market players are undertaking several activities to grab a major share of the market and hold a leading position in the antiviral therapies industry. Some of these activities include new product launches, mergers and acquisitions, antiviral therapy market developments in current technology. These are some of the growth strategies implemented by these market players.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
+1 (917) 444-1262 (US) Toll
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com

Categories
Top stories

Antiviral therapies Market forecast surpass $66,016.5 Million in 2027, growing at a 3.1% CAGR From $51,913.1 Million

Global Antiviral Therapy Market size is expected to grow with a CAGR of 5.8% from 2019 to 2026 According to a study conducted by Research Dive. The global antiviral therapy market size was accounted at $48.1 billion in 2018 and is anticipated to garner $ 75.6 billion by 2026.

Increasing incidences of viral infections, growing awareness among public about these infections, rise in healthcare spending, growing R&D investments, and growing incidences of severe and deadly disorders in people are the key antiviral therapy market drivers responsible to boost the growth of global market during estimated period. In addition, development of broad-spectrum antibiotics and surge in profitable opportunities in the developing economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities for the growth of the market. On the other hand, huge costs involved in the manufacturing of these therapy and rise in the demand for alternative medicines such as homeopathy and naturopathy are expected to restrain the development of the market.

The HIV segment in the antiviral therapy market was valued at $16.4 billion in the year 2018 and is expected to increase with a growth rate of 5.4% throughout the estimated period. This is because of the rising occurrence of HIV infection across the globe. The majority of HIV antiviral drug usage has been seen in the North America region. Also, the consumption of antiviral therapy in African region is expected to increase and fuel the development of the market.

The online pharmacy segment is expected to grow at an increased speed by generating a revenue of $23.2 billion by the end of 2026, at a significant growth rate of 6.1% during the forecast period. On the other hand, the hospital pharmacy segment is anticipated to dominate the market by generating a revenue of $35.5 billion by the end of 2026, at a substantial growth rate of 5.5% throughout the forecast period. This is mainly due growing trends in the online shopping sector in the developed and developing countries. At present, the market share is mainly controlled by a few top pharmaceuticals as well as biotechnology companies.

Regionally, the market has been studied across Asia-Pacific, North America, Europe, and LAMEA. Asia-Pacific antiviral therapy market is anticipated to grow at an increased pace with a healthy growth rate of 6.5% during the forecast period, garnering $12.8 billion by the end of 2026. This is mainly due to factors such as the growing cases of HIV infection, growing awareness about HIV infection, and increasing collaboration between public and private sectors in this region. Furthermore, the North America antiviral therapy market held a leading position in the global antiviral therapy market in 2018. This region is anticipated to hold its lead position in the market throughout the forecast period by generating a revenue of $29.5 billion by 2026. This is attributed to factors such as the rising occurrence of HIV and hepatitis C infections, well-established market players in the region, growing healthcare awareness, rising elderly population, and increasing healthcare spending in this region. On the contrary, factors such as patent expiration and generic erosion of antiviral therapy are hindering the growth of the market in this region.

The key market players profiled in the report are F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Abbott Laboratories, AbbVie Inc., AstraZeneca Plc., Bristol- Myers-Squibb, Johnson & Johnson, Schering-Plough Corporation, and Merck & Co., Inc. These market players are undertaking several activities to grab a major share of the market and hold a leading position in the antiviral therapies industry. Some of these activities include new product launches, mergers and acquisitions, antiviral therapy market developments in current technology. These are some of the growth strategies implemented by these market players.

Contact Us:

Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York
NY 10005 (P)
+ 91 (788) 802-9103 (India)
+1 (917) 444-1262 (US) Toll
Free : +1 -888-961-4454
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/research-dive
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive
Blog: https://www.researchdive.com/blog
Follow us on: https://covid-19-market-insights.blogspot.com